| Symbol | APUS |
|---|---|
| Name | APIMEDS PHARMACEUTICALS US, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 100 MATAWAN RD, MATAWAN, NJ 07747 |
| Telephone | 848-201-5010 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001894525 |
| Description | None |
New Form NT 10-Q - Apimeds Pharmaceuticals US, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001213900-26-057713 <b>Size:</b> 20 KB
Read moreNew Form SCHEDULE 13D/A - Apimeds Pharmaceuticals US, Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001213900-26-053091 <b>Size:</b> 16 KB
Read moreApimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
Read more(99% Neutral) APIMEDS PHARMACEUTICALS US, INC. (APUS) Announces New Board Appointment
Read more(50% Neutral) APIMEDS PHARMACEUTICALS US, INC. (APUS) Announces Business Combination
Read moreNew Form 10-K - Apimeds Pharmaceuticals US, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001213900-26-051139 <b>Size:</b> 6 MB
Read more(70% Positive) APIMEDS PHARMACEUTICALS US, INC. (APUS) Reports Q2 2026 Financial Results
Read more(99% Neutral) APIMEDS PHARMACEUTICALS US, INC. (APUS) Announces Update on Collaboration with Apimeds Pharmaceuticals US
Read moreApimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
Read moreRosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
Read more